Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors

AIDS Research and Human Retroviruses

Volumn 16, Issue 13, 2000, Pages 1209-1213

  Bally, F ^a   Martinez, R ^a   Peters, S ^a   Sudre, P ^a   Telenti, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; CELL COUNT; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME INHIBITION; EVOLUTION; GENE MUTATION; GENETIC POLYMORPHISM; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRUS LOAD;

CAPSID; CAPSID PROTEINS; DISEASE PROGRESSION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL PROTEINS;

EID: 0034284897     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050116970     Document Type: Article

References (15)

1. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
2. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
3. Antiretroviral drug resistance testing in adults with HIV infection
4. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
5. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
6. Mutations selected in HIV plasma RNA daring 141W94 therapy
7. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
8. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
9. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
10. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
11. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes
12. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid
13. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression
14. HIV-1 cleavage site changes are associated with specific protease mutations in plasma HIV-1 RNA but are not always retained in replication-competent, protease inhibitor-resistant recombinant viruses
15. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients